$CBT
CABOT CORP

2022 Q1 Form 10-Q Financial Statement

#000156459022018821 Filed on May 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $1.092B $842.0M
YoY Change 29.69% 18.59%
Cost Of Revenue $860.0M $628.0M
YoY Change 36.94% 13.56%
Gross Profit $232.0M $214.0M
YoY Change 8.41% 36.31%
Gross Profit Margin 21.25% 25.42%
Selling, General & Admin $74.00M $71.00M
YoY Change 4.23% 12.7%
% of Gross Profit 31.9% 33.18%
Research & Development $14.00M $14.00M
YoY Change 0.0% 0.0%
% of Gross Profit 6.03% 6.54%
Depreciation & Amortization $36.00M $38.00M
YoY Change -5.26% -2.56%
% of Gross Profit 15.52% 17.76%
Operating Expenses $88.00M $85.00M
YoY Change 3.53% 10.39%
Operating Profit $144.0M $129.0M
YoY Change 11.63% 61.25%
Interest Expense -$7.000M -$11.00M
YoY Change -36.36% 0.0%
% of Operating Profit -4.86% -8.53%
Other Income/Expense, Net -$7.000M $1.000M
YoY Change -800.0% -200.0%
Pretax Income $147.0M $118.0M
YoY Change 24.58% 883.33%
Income Tax $36.00M $34.00M
% Of Pretax Income 24.49% 28.81%
Net Earnings $107.0M $75.00M
YoY Change 42.67% -7600.0%
Net Earnings / Revenue 9.8% 8.91%
Basic Earnings Per Share $1.86 $1.31
Diluted Earnings Per Share $1.84 $1.30
COMMON SHARES
Basic Shares Outstanding 56.60M 56.60M
Diluted Shares Outstanding 57.10M 56.70M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $215.0M $146.0M
YoY Change 47.26% 2.82%
Cash & Equivalents $215.0M $150.0M
Short-Term Investments
Other Short-Term Assets $139.0M $64.00M
YoY Change 117.19% -34.69%
Inventory $633.0M $436.0M
Prepaid Expenses
Receivables $791.0M $578.0M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.778B $1.224B
YoY Change 45.26% 4.53%
LONG-TERM ASSETS
Property, Plant & Equipment $1.291B $1.334B
YoY Change -3.22% -9.07%
Goodwill $141.0M $139.0M
YoY Change 1.44% 69.51%
Intangibles
YoY Change
Long-Term Investments $16.00M $40.00M
YoY Change -60.0% 11.11%
Other Assets $228.0M $207.0M
YoY Change 10.14% 21.05%
Total Long-Term Assets $1.746B $1.823B
YoY Change -4.22% -5.35%
TOTAL ASSETS
Total Short-Term Assets $1.778B $1.224B
Total Long-Term Assets $1.746B $1.823B
Total Assets $3.524B $3.047B
YoY Change 15.65% -1.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $737.0M $562.0M
YoY Change 31.14% 9.77%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $253.0M $44.00M
YoY Change 475.0%
Long-Term Debt Due $373.0M $8.000M
YoY Change 4562.5% 14.29%
Total Short-Term Liabilities $1.407B $647.0M
YoY Change 117.47% 14.92%
LONG-TERM LIABILITIES
Long-Term Debt $711.0M $1.087B
YoY Change -34.59% -8.66%
Other Long-Term Liabilities $267.0M $308.0M
YoY Change -13.31% 14.93%
Total Long-Term Liabilities $978.0M $1.395B
YoY Change -29.89% -4.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.407B $647.0M
Total Long-Term Liabilities $978.0M $1.395B
Total Liabilities $2.606B $2.236B
YoY Change 16.55% 2.95%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $4.000M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $918.0M $811.0M
YoY Change
Total Liabilities & Shareholders Equity $3.524B $3.047B
YoY Change 15.65% -1.61%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income $107.0M $75.00M
YoY Change 42.67% -7600.0%
Depreciation, Depletion And Amortization $36.00M $38.00M
YoY Change -5.26% -2.56%
Cash From Operating Activities $10.00M $65.00M
YoY Change -84.62% 170.83%
INVESTING ACTIVITIES
Capital Expenditures -$41.00M -$40.00M
YoY Change 2.5% -21.57%
Acquisitions
YoY Change
Other Investing Activities $85.00M $3.000M
YoY Change 2733.33% 50.0%
Cash From Investing Activities $44.00M -$37.00M
YoY Change -218.92% -24.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -18.00M 11.00M
YoY Change -263.64% -79.63%
NET CHANGE
Cash From Operating Activities 10.00M 65.00M
Cash From Investing Activities 44.00M -37.00M
Cash From Financing Activities -18.00M 11.00M
Net Change In Cash 36.00M 39.00M
YoY Change -7.69% 34.48%
FREE CASH FLOW
Cash From Operating Activities $10.00M $65.00M
Capital Expenditures -$41.00M -$40.00M
Free Cash Flow $51.00M $105.0M
YoY Change -51.43% 40.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
24000000
us-gaap Profit Loss
ProfitLoss
34000000
us-gaap Profit Loss
ProfitLoss
155000000
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
3000000
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
3000000
cbt Other Comprehensive Income Loss Net Investment Hedges Gain Loss Excluded From Effectiveness Testing And Amortized To Interest Expense Net Of Tax
OtherComprehensiveIncomeLossNetInvestmentHedgesGainLossExcludedFromEffectivenessTestingAndAmortizedToInterestExpenseNetOfTax
1000000
cbt Other Comprehensive Income Loss Net Investment Hedges Gain Loss Excluded From Effectiveness Testing And Amortized To Interest Expense Net Of Tax
OtherComprehensiveIncomeLossNetInvestmentHedgesGainLossExcludedFromEffectivenessTestingAndAmortizedToInterestExpenseNetOfTax
1000000
CY2021Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
-1000000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
-2000000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
4000000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1000000
us-gaap Profit Loss
ProfitLoss
34000000
us-gaap Profit Loss
ProfitLoss
155000000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
16000000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
20000000
us-gaap Net Income Loss
NetIncomeLoss
18000000
us-gaap Net Income Loss
NetIncomeLoss
135000000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56500000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56600000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56900000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56700000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.37
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
-4000000
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-1000000
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-3000000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
18000000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
20000000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
52000000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
175000000
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
10000000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
16000000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
20000000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
1000000
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
-2000000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
3000000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
5000000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
8000000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
8000000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
19000000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
25000000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
152000000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1000000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
33000000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
150000000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
215000000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
168000000
CY2021Q3 us-gaap Allowance For Notes And Loans Receivable Current
AllowanceForNotesAndLoansReceivableCurrent
4000000
CY2022Q1 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
791000000
CY2021Q3 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
645000000
CY2022Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
193000000
CY2021Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
168000000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
1778000000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
1425000000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1291000000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1376000000
CY2022Q1 us-gaap Goodwill
Goodwill
141000000
CY2021Q3 us-gaap Goodwill
Goodwill
140000000
CY2022Q1 us-gaap Equity Method Investments
EquityMethodInvestments
16000000
CY2021Q3 us-gaap Equity Method Investments
EquityMethodInvestments
40000000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
70000000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
100000000
CY2022Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
63000000
CY2021Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
53000000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
172000000
CY2021Q3 us-gaap Assets
Assets
3306000000
CY2022Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
73000000
CY2021Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
73000000
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
1
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
1
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56571822
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56870237
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56431554
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56726818
CY2022Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
140268
CY2021Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
143419
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
4000000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
24000000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1159000000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-289000000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
947000000
CY2021Q3 us-gaap Minority Interest
MinorityInterest
143000000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1090000000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3306000000
us-gaap Profit Loss
ProfitLoss
34000000
us-gaap Profit Loss
ProfitLoss
155000000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
75000000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
77000000
us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
-204000000
us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
24000000
us-gaap Increase Decrease In Pension And Postretirement Obligations
IncreaseDecreaseInPensionAndPostretirementObligations
6000000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
4000000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1000000
us-gaap Share Based Compensation
ShareBasedCompensation
11000000
us-gaap Share Based Compensation
ShareBasedCompensation
10000000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-8000000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-19000000
us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
161000000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
177000000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
55000000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
84000000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
10000000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15000000
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
13000000
us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
1000000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
40000000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1000000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
150000000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
215000000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
150000000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1090000000
CY2021Q4 us-gaap Profit Loss
ProfitLoss
-80000000
CY2021Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-28000000
CY2021Q4 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.37
CY2021Q4 us-gaap Dividends
Dividends
21000000
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6000000
CY2021Q4 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
19000000
CY2022Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.37
CY2022Q1 us-gaap Dividends
Dividends
21000000
CY2022Q1 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
15000000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1066000000
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
814000000
CY2020Q4 us-gaap Profit Loss
ProfitLoss
70000000
CY2020Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
96000000
CY2020Q4 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.35
CY2020Q4 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
1000000
CY2020Q4 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
2000000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
962000000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
85000000
CY2021Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.35
CY2021Q1 us-gaap Dividends
Dividends
20000000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1000000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6000000
CY2021Q3 us-gaap Goodwill
Goodwill
140000000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
1000000
CY2022Q1 us-gaap Goodwill
Goodwill
141000000
CY2022Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
100000000
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
30000000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
70000000
CY2021Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
133000000
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
33000000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
100000000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
6000000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
6000000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
6000000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
6000000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
6000000
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">G. Contingencies</p> <p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Respirator Liabilities</p> <p style="margin-top:4pt;margin-bottom:0pt;text-indent:3.4%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cabot has exposure in connection with a safety respiratory products business that a subsidiary acquired from American Optical Corporation (“AO”) in an April 1990 asset purchase transaction. The subsidiary manufactured respirators under the AO brand and disposed of that business in July 1995. In connection with its acquisition of the business, the subsidiary agreed, in certain circumstances, to assume a portion of AO’s liabilities, including costs of legal fees together with amounts paid in settlements and judgments, allocable to AO respiratory products used prior to the 1990 purchase by the Cabot subsidiary. In exchange for the subsidiary’s assumption of certain of AO’s respirator liabilities, AO agreed to provide to the subsidiary the benefits of: (i) AO’s insurance coverage for the period prior to the 1990 acquisition and (ii) a former owner’s indemnity of AO holding it harmless from any liability allocable to AO respiratory products used prior to May 1982. As more fully described in the 2021 10-K, the respirator liabilities generally involve claims for personal injury, including asbestosis, silicosis and coal worker’s pneumoconiosis, allegedly resulting from the use of respirators that are alleged to have been negligently designed and/or labeled. At no time did this respiratory product line represent a significant portion of the respirator market. In addition to Cabot’s subsidiary, other parties are responsible for significant portions of the costs of these respirator liabilities (as defined in the 2021 10-K, the “Payor Group”).</p> <p style="margin-top:4pt;margin-bottom:0pt;text-indent:3.4%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cabot has a reserve to cover its expected share of liabilities for pending and future respirator liability claims, which is included in Other liabilities and Accounts payable and accrued liabilities on the Consolidated Balance Sheets. The Company expects these liabilities to be incurred over a number of years.<span style="font-family:Times New Roman;"> </span>The reserve balance decreased from $44 million at September 30, 2021 to $42 million at March 31, 2022, representing the net impact from a charge to the reserve and settlement payments made during the six month period ended March 31, 2022. </p> <p style="margin-top:4pt;margin-bottom:0pt;text-indent:3.4%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s current estimate of the cost of its share of pending and future respirator liability claims is based on facts and circumstances existing at this time, including the number and nature of the remaining claims. Developments that could affect the Company’s estimate include, but are not limited to, (i) significant changes in the number of future claims, (ii) changes in the rate of dismissals without payment of pending claims, (iii) significant changes in the average cost of resolving claims, including potential settlements of groups of claims, (iv) significant changes in the legal costs of defending these claims, (v) changes in the nature of claims received or changes in our assessment of the viability of these claims, (vi) trial and appellate outcomes, (vii) changes in the law and procedure applicable to these claims, (viii) the financial viability of the parties that contribute to the payment of respirator claims, (ix) exhaustion or changes in the recoverability of the insurance coverage maintained by certain members of the Payor Group, or a change in the availability of the indemnity provided by a former owner of AO, (x) changes in the allocation of costs among the various parties paying legal and settlement costs, and (xi) a determination that the assumptions that were used to estimate Cabot’s share of liability are no longer reasonable. The Company cannot determine the impact of these potential developments on its current estimate of its share of liability for existing and future claims. Because reserves are limited to amounts that are probable and estimable as of a relevant measurement date, and there is inherent difficulty in projecting the impact of </p> <p style="margin-top:4pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potential developments on Cabot’s share of liability for these existing and future claims, it is reasonably possible that the liabilities for existing and future claims could change in the near term and that change could be material</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p> <p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Other Matters</p> <p style="margin-top:4pt;margin-bottom:0pt;text-indent:3.4%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has various other lawsuits, claims and contingent liabilities arising in the ordinary course of its business and with respect to its divested businesses. The Company does not believe that any of these matters will have a material adverse effect on its financial position; however, litigation is inherently unpredictable. Cabot could incur judgments, enter into settlements or revise its expectations regarding the outcome of certain matters, and such developments could have a material impact on its results of operations in the period in which the amounts are accrued or its cash flows in the period in which the amounts are paid.</p>
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
36000000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
34000000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
24000000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
63000000
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.24
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.29
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.44
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.29
CY2022Q1 cbt Net Discrete Tax Benefits Charges Related To Tax Settlements
NetDiscreteTaxBenefitsChargesRelatedToTaxSettlements
1000000
cbt Net Discrete Tax Benefits Charges Related To Tax Settlements
NetDiscreteTaxBenefitsChargesRelatedToTaxSettlements
-36000000
CY2021Q1 cbt Net Discrete Tax Benefits Charges Related To Tax Settlements
NetDiscreteTaxBenefitsChargesRelatedToTaxSettlements
-1000000
cbt Net Discrete Tax Benefits Charges Related To Tax Settlements
NetDiscreteTaxBenefitsChargesRelatedToTaxSettlements
1000000
CY2022Q1 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
1000000
us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
2000000
us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
1000000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
107000000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
75000000
us-gaap Net Income Loss
NetIncomeLoss
18000000
us-gaap Net Income Loss
NetIncomeLoss
135000000
CY2022Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1000000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1000000
CY2022Q1 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
1000000
CY2021Q1 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
1000000
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
1000000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
105000000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
74000000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
17000000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
134000000
CY2022Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
57500000
CY2021Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
57400000
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
57400000
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
57300000
CY2022Q1 cbt Participating Securities
ParticipatingSecurities
900000
CY2021Q1 cbt Participating Securities
ParticipatingSecurities
800000
cbt Participating Securities
ParticipatingSecurities
900000
cbt Participating Securities
ParticipatingSecurities
700000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56600000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56600000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56500000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56600000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.86
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.37
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
105000000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
74000000
CY2022Q1 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
2000000
CY2021Q1 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
1000000
us-gaap Participating Securities Distributed And Undistributed Earnings Loss Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
1000000
us-gaap Participating Securities Distributed And Undistributed Earnings Loss Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
1000000
CY2022Q1 cbt Adjusted Earnings Loss Allocated To Participating Securities
AdjustedEarningsLossAllocatedToParticipatingSecurities
-2000000
CY2021Q1 cbt Adjusted Earnings Loss Allocated To Participating Securities
AdjustedEarningsLossAllocatedToParticipatingSecurities
-1000000
cbt Adjusted Earnings Loss Allocated To Participating Securities
AdjustedEarningsLossAllocatedToParticipatingSecurities
-1000000
cbt Adjusted Earnings Loss Allocated To Participating Securities
AdjustedEarningsLossAllocatedToParticipatingSecurities
-1000000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
105000000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
74000000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
17000000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
134000000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56600000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56600000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56500000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56600000
CY2022Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
500000
CY2021Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
100000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57100000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56700000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56900000
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.84
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.30
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
107000000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
75000000
us-gaap Net Income Loss
NetIncomeLoss
18000000
CY2022Q1 us-gaap Dividends Common Stock
DividendsCommonStock
21000000
CY2021Q1 us-gaap Dividends Common Stock
DividendsCommonStock
20000000
us-gaap Dividends Common Stock
DividendsCommonStock
42000000
CY2022Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
1000000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
1000000
CY2022Q1 us-gaap Undistributed Earnings
UndistributedEarnings
85000000
cbt Undistributed Loss Earnings Allocated To Common Shareholders
UndistributedLossEarningsAllocatedToCommonShareholders
94000000
CY2021Q1 cbt Undistributed Loss Earnings Allocated To Participating Shareholders
UndistributedLossEarningsAllocatedToParticipatingShareholders
1000000
cbt Undistributed Loss Earnings Allocated To Participating Shareholders
UndistributedLossEarningsAllocatedToParticipatingShareholders
1000000
CY2021Q1 us-gaap Undistributed Earnings
UndistributedEarnings
55000000
us-gaap Undistributed Earnings
UndistributedEarnings
-25000000
us-gaap Undistributed Earnings
UndistributedEarnings
95000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
356476
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1120460
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1377609
CY2022Q1 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2022Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2022Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q1 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2022Q1 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
1070000000.00
CY2021Q3 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
1130000000
CY2022Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2022Q1 us-gaap Revenues
Revenues
1092000000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
147000000
CY2021Q1 us-gaap Revenues
Revenues
842000000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
118000000
us-gaap Revenues
Revenues
2060000000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
54000000
us-gaap Revenues
Revenues
1588000000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
217000000
CY2022Q1 cbt Percentage Of Sale Of Equity Method Affiliates
PercentageOfSaleOfEquityMethodAffiliates
1
CY2021Q1 cbt Percentage Of Sale Of Equity Method Affiliates
PercentageOfSaleOfEquityMethodAffiliates
1
cbt Percentage Of Sale Of Equity Method Affiliates
PercentageOfSaleOfEquityMethodAffiliates
1
cbt Percentage Of Sale Of Equity Method Affiliates
PercentageOfSaleOfEquityMethodAffiliates
1
CY2022Q1 us-gaap Revenues
Revenues
1092000000
CY2021Q1 us-gaap Revenues
Revenues
842000000
us-gaap Revenues
Revenues
2060000000
us-gaap Revenues
Revenues
1588000000

Files In Submission

Name View Source Status
0001564590-22-018821-index-headers.html Edgar Link pending
0001564590-22-018821-index.html Edgar Link pending
0001564590-22-018821.txt Edgar Link pending
0001564590-22-018821-xbrl.zip Edgar Link pending
cbt-10q_20220331.htm Edgar Link pending
cbt-10q_20220331_htm.xml Edgar Link completed
cbt-20220331.xsd Edgar Link pending
cbt-20220331_cal.xml Edgar Link unprocessable
cbt-20220331_def.xml Edgar Link unprocessable
cbt-20220331_lab.xml Edgar Link unprocessable
cbt-20220331_pre.xml Edgar Link unprocessable
cbt-ex311_7.htm Edgar Link pending
cbt-ex312_6.htm Edgar Link pending
cbt-ex32_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending